Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Almujtama Alraida Medical CoSAU:9592 13 ROE % is 6.14% as of Dec. 2025, which is 59% below its 10-year median of 15.09. GuruFocus rates SAU:9592 with a GF Score™ of 13/100. The stock has 4 warning signs investors should review. Among 622 Healthcare Providers & Services companies, Almujtama Alraida Medical Co ranks worse than 50.32% on this metric.
Almujtama Alraida Medical Co (SAU:9592) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Almujtama Alraida Medical Co ROE % Related Terms
Almujtama Alraida Medical Co ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Almujtama Alraida Medical Co ROE % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Almujtama Alraida Medical Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Almujtama Alraida Medical Co ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Almujtama Alraida Medical Co's ROE % distribution charts can be found below:
* The bar in red indicates where Almujtama Alraida Medical Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Almujtama Alraida Medical Co (SAU:9592) has a ROE % of 6.14% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Almujtama Alraida Medical Co and its competitors. This is 59% below median its historical median of 15.09. Over the past decade, Almujtama Alraida Medical Co's ROE % has ranged from 6.19 to 89.74. According to the industry distribution chart, Almujtama Alraida Medical Co ranks #313 out of 622 companies in the Healthcare Providers & Services industry, placing it in the top 50.3%.
Is Almujtama Alraida Medical Co's ROE % too high?
Almujtama Alraida Medical Co's current ROE % of 6.14% is 59% below median its 10-year median of 15.09. Over the past 10 years, this metric has ranged from a low of 6.19 to a high of 89.74. The Healthcare Providers & Services industry median ROE % is 6.28. Almujtama Alraida Medical Co's value of 6.14% is 2.2% below this industry median. Based on the distribution chart, Almujtama Alraida Medical Co ranks #313 out of 622 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Almujtama Alraida Medical Co has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Almujtama Alraida Medical Co's ROE % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Almujtama Alraida Medical Co ranks #313 out of 622 companies for ROE %. This places Almujtama Alraida Medical Co in the lower half of its industry. The industry median ROE % is 6.28. Almujtama Alraida Medical Co's value of 6.14% is 2.2% below this benchmark. Historically, Almujtama Alraida Medical Co's own ROE % has ranged from 6.19 to 89.74 over the past decade. While the company's 10-year median is 15.09 vs. the industry median of 6.28, Almujtama Alraida Medical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 6.28, based on 622 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Almujtama Alraida Medical Co's current ROE % of 6.14% is 2.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Almujtama Alraida Medical Co and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 6.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Almujtama Alraida Medical Co's current ROE % is 6.14%, which is 59% below median its own 10-year median of 15.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Almujtama Alraida Medical Co stock overvalued right now?
Almujtama Alraida Medical Co (SAU:9592) has a current ROE % of 6.14%. The current ROE % is 6.14%, which is 59% below median its 10-year median of 15.09 and 2.2% below the Healthcare Providers & Services industry median of 6.28. Almujtama Alraida Medical Co's overall GF Score™ is 13/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Almujtama Alraida Medical Co (SAU:9592), the current ROE % is 6.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Almujtama Alraida Medical Co is a company having its core operations include operating pharmacies and retailing pharmaceutical products such as medicines and cosmetic products and medical equipment and medical supplies. It also provides pharmaceutical services in the Kingdom of Saudi Arabia.
13GF Score
Get the complete analysis for SAU:9592
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:9592 has been successfully added to your 
